메뉴 건너뛰기




Volumn 152, Issue 17, 2011, Pages 655-662

Novelties of treatment in advanced renal-cell cancer;Új lehetoségek a vesedaganatok onkológiai kezelésében

Author keywords

mTOR inhibitors; renal cell cancer; target therapy; tyrosine kinase inhibitors; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

EID: 79953824378     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29100     Document Type: Review
Times cited : (1)

References (37)
  • 2
    • 33644636306 scopus 로고    scopus 로고
    • A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei
    • Ottó Sz., Kásler M.: A hazai és nemzetközi daganatos halálozási és megbetegedési mutatók alakulása. A népegészségügyi programok jellegzetességei és várható eredményei. Magy. Onkol., 2005, 49, 99-107.
    • (2005) Magy. Onkol. , vol.49 , pp. 99-107
    • Ottó, Sz.1    Kásler, M.2
  • 3
    • 55049123815 scopus 로고    scopus 로고
    • Systemic therapy for metastatic renal cell carcinoma
    • Kroog, G. S., Motzer, R. J.: Systemic therapy for metastatic renal cell carcinoma. Urol. Clin. North Am., 2008, 35, 687-701.
    • (2008) Urol. Clin. North Am. , vol.35 , pp. 687-701
    • Kroog, G.S.1    Motzer, R.J.2
  • 4
    • 34250332941 scopus 로고    scopus 로고
    • Common and uncommon histologic subtypes of renal cell carcinoma: Imaging spectrum with pathologic correlation
    • Prasad, S. R., Humphrey, P. A., Catena, J. R. és mtsai: Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. RadioGraphics, 2006, 26, 1795-1810.
    • (2006) RadioGraphics , vol.26 , pp. 1795-1810
    • Prasad, S.R.1    Humphrey, P.A.2    Catena, J.R.3
  • 5
    • 0042821661 scopus 로고    scopus 로고
    • Chemotherapeutic strategies for renal cell carcinoma
    • Milowsky, M. I., Nanus, D. M.: Chemotherapeutic strategies for renal cell carcinoma. Urol. Clin. North Am., 2003, 30, 601-609.
    • (2003) Urol. Clin. North Am. , vol.30 , pp. 601-609
    • Milowsky, M.I.1    Nanus, D.M.2
  • 6
    • 0035134688 scopus 로고    scopus 로고
    • Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities
    • DOI 10.1634/theoncologist.6-1-34
    • Jonasch, E., Haluska, F. G.: Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 2001, 6, 34-55. (Pubitemid 32155814)
    • (2001) Oncologist , vol.6 , Issue.1 , pp. 34-55
    • Jonasch, E.1    Haluska, F.G.2
  • 7
    • 34248547900 scopus 로고    scopus 로고
    • A világossejtes veserák célzott terá piája és molekuláris patológiai alapjai
    • Tímár J., Kopper L., Bodrogi I.: A világossejtes veserák célzott terápiája és molekuláris patológiai alapjai. Magyar Onkológia, 2006, 50, 309-314.
    • (2006) Magyar Onkológia , vol.50 , pp. 309-314
    • Tímár, J.1    Kopper, L.2    Bodrogi, I.3
  • 8
    • 77953757715 scopus 로고    scopus 로고
    • Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma
    • Schmidinger, M., Bellmunt, J.: Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev., 2010, 36, 416-424.
    • (2010) Cancer Treat. Rev. , vol.36 , pp. 416-424
    • Schmidinger, M.1    Bellmunt, J.2
  • 9
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer, R. J., Bacik, J., Murphy, B. A. és mtsai: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol., 2002, 20, 289-296.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3
  • 10
    • 77954326508 scopus 로고    scopus 로고
    • Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • On behalf of the ESMO Guidelines Working Group
    • Escudier, B., Kataja, V.: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. On behalf of the ESMO Guidelines Working Group. Ann. Oncol., 2010, 21 (Suppl. 5), v137-v139.
    • (2010) Ann. Oncol. , vol.21 , Issue.SUPPL. 5
    • Escudier, B.1    Kataja, V.2
  • 11
    • 79251574372 scopus 로고    scopus 로고
    • Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    • Patil, S., Figlin, R. A., Hutson, T. E. és mtsai: Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol., 2011, 22, 295-300.
    • (2011) Ann. Oncol. , vol.22 , pp. 295-300
    • Patil, S.1    Figlin, R.A.2    Hutson, T.E.3
  • 12
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • Motzer, R. J., Escudier, B., Oudard, S. és mtsai: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, 2008, 372, 449-456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 13
    • 1342288873 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor protein in human renal cell carcinoma
    • Jacobsen, J., Grankvist, K., Rasmuson, T. és mtsai: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int., 2004, 93, 297-302.
    • (2004) BJU Int. , vol.93 , pp. 297-302
    • Jacobsen, J.1    Grankvist, K.2    Rasmuson, T.3
  • 14
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer
    • Willett, C. G., Boucher, Y., di Tomaso, E. és mtsai: Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10, 145-147.
    • (2004) Nat. Med. , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    Di Tomaso, E.3
  • 15
    • 77955880263 scopus 로고    scopus 로고
    • Emerging drugs for renal cell cancer
    • Varella, L., Rini, B. I.: Emerging drugs for renal cell cancer. Expert Opin. Emerg. Drugs, 2010, 15, 343-353.
    • (2010) Expert Opin. Emerg. Drugs , vol.15 , pp. 343-353
    • Varella, L.1    Rini, B.I.2
  • 16
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang, J. C., Haworth, L., Sherry, R. M. és mtsai: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med., 2003, 349, 427-434.
    • (2003) N. Engl. J. Med. , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 18
    • 43249085165 scopus 로고    scopus 로고
    • CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma
    • Presented at Abstract 350
    • Rini, B., Halabi, S., Rosenberg, J. és mtsai: CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha monotherapy in metastatic renal cell carcinoma. Presented at Geni-tourinary Cancers Symposium, 2008, p. 267. Abstract 350.
    • Geni-tourinary Cancers Symposium, 2008 , pp. 267
    • Rini, B.1    Halabi, S.2    Rosenberg, J.3
  • 19
    • 0035990893 scopus 로고    scopus 로고
    • Protein kinases as targets for anticancer agents: From inhibitors to useful drugs
    • Fabbro, D., Ruetz, S., Buchdunger, E. és mtsai: Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther., 2002, 93, 79-98.
    • (2002) Pharmacol. Ther. , vol.93 , pp. 79-98
    • Fabbro, D.1    Ruetz, S.2    Buchdunger, E.3
  • 20
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal cell carcinoma
    • Escudier, B., Eisen, T., Stadler, W. M. és mtsai: Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med., 2007, 356, 125-134.
    • (2007) N. Engl. J. Med. , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 21
    • 77952207351 scopus 로고    scopus 로고
    • Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: Report of two cases and literature review
    • Kamada, P., Dudek, A. Z.: Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest., 2010, 28, 501-504.
    • (2010) Cancer Invest. , vol.28 , pp. 501-504
    • Kamada, P.1    Dudek, A.Z.2
  • 22
    • 62449186539 scopus 로고    scopus 로고
    • Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma
    • Escudier, B., Szczylik, C., Hutson, T. E. és mtsai: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27, 1280-1289.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1280-1289
    • Escudier, B.1    Szczylik, C.2    Hutson, T.E.3
  • 23
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer, R. J., Michaelson, M. D., Redman, B. G. és mtsai: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 16-24.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 25
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer, R. J., Hutson, T. E., Tomczak, P. és mtsai: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 115-124.
    • (2007) N. Engl. J. Med. , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 26
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • Motzer, R. J., Hutson, T. E., Tomczak, P. és mtsai: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2009, 27, 3584-3590.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 27
    • 60849102835 scopus 로고    scopus 로고
    • Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma
    • Hutson, T. E.: Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. Expert Rev. Anticancer Ther., 2008, 8, 1723-1731.
    • (2008) Expert Rev. Anticancer Ther. , vol.8 , pp. 1723-1731
    • Hutson, T.E.1
  • 28
    • 77949429364 scopus 로고    scopus 로고
    • Sunitinib for the management of advanced renal cell carcinoma
    • Escudier, B.: Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther., 2010, 10, 305-317.
    • (2010) Expert Rev. Anticancer Ther. , vol.10 , pp. 305-317
    • Escudier, B.1
  • 29
    • 72549101585 scopus 로고    scopus 로고
    • Neoadjuvant treatment of renal cell carcinoma
    • Rathmell, W. K., Pruthi, R., Wallen, E.: Neoadjuvant treatment of renal cell carcinoma. Urol. Oncol., 2010, 28, 69-73.
    • (2010) Urol. Oncol. , vol.28 , pp. 69-73
    • Rathmell, W.K.1    Pruthi, R.2    Wallen, E.3
  • 30
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg, C. N., Davis, I. D., Mardiak, J. és mtsai: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J. Clin. Oncol., 2010, 28, 1061-1068.
    • (2010) J. Clin. Oncol. , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 31
    • 79551584678 scopus 로고    scopus 로고
    • Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): Final overall survival (OS) results
    • Abstract LBA22
    • Sternberg, C. N., Hawkins, R. E., Szczylik, C. és mtsai: Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): final overall survival (OS) results. Ann. Oncol., 2010, 21 (Suppl. 8), Abstract LBA22.
    • (2010) Ann. Oncol. , vol.21 , Issue.SUPPL. 8
    • Sternberg, C.N.1    Hawkins, R.E.2    Szczylik, C.3
  • 32
    • 77958043734 scopus 로고    scopus 로고
    • Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    • Goldstein, R., Pickering, L., Larkin, J.: Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Expert Rev. Anticancer Ther., 2010, 10, 1545-1557.
    • (2010) Expert Rev. Anticancer Ther. , vol.10 , pp. 1545-1557
    • Goldstein, R.1    Pickering, L.2    Larkin, J.3
  • 33
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes, G., Carducci, M., Tomczak, P. és mtsai: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 2271-2281.
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 34
    • 79953810848 scopus 로고    scopus 로고
    • Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
    • Abstr. 4608
    • Osanto, S., Hutson, T. E., Calvo, E. és mtsai: Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol., 2010, 28 (May 20 Suppl.), Abstr. 4608.
    • (2010) J. Clin. Oncol. , vol.28 , Issue.MAY 20 SUPPL.
    • Osanto, S.1    Hutson, T.E.2    Calvo, E.3
  • 35
    • 39649122843 scopus 로고    scopus 로고
    • A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    • Patel, T. V., Morgan, J. A., Demetri, G. D. és mtsai: A preeclampsia- like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J. Natl. Cancer Inst., 2008, 100, 282-284.
    • (2008) J. Natl. Cancer Inst. , vol.100 , pp. 282-284
    • Patel, T.V.1    Morgan, J.A.2    Demetri, G.D.3
  • 36
    • 78649379884 scopus 로고    scopus 로고
    • How to select targeted therapy in renal cell cancer
    • Escudier, B., Albiges, L., Blesius, A. és mtsai: How to select targeted therapy in renal cell cancer. Ann. Oncol., 2010, 21 (Suppl. 7), vii59-vii62.
    • (2010) Ann. Oncol. , vol.21 , Issue.SUPPL. 7
    • Escudier, B.1    Albiges, L.2    Blesius, A.3
  • 37
    • 79953808494 scopus 로고    scopus 로고
    • Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: Focus on mechanism of action
    • Oudard, S., Ravaud, A., Escudier, B.: Sequencing of therapeutic agents in the treatment of advanced renal cell carcinoma: Focus on mechanism of action. Annals of Urology, 2010, 10, 4.
    • (2010) Annals of Urology , vol.10 , pp. 4
    • Oudard, S.1    Ravaud, A.2    Escudier, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.